Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?

This article was originally published in The Gray Sheet

Executive Summary

Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company

You may also be interested in...



Novartis/Alcon Merger Clears FTC Hurdle With Minor Divestiture, But Shareholder Battle Continues

Novartis sells its miotic drug Miochol-E to Bausch & Lomb to avoid anticompetitive charges; a Novartis legal expert says a subset of Alcon's board cannot veto the transaction.

Novartis Completes Deal For Nestle's Share In Alcon

For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008

Novartis Completes Deal For Nestle's Share In Alcon

For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008

Related Content

Topics

UsernamePublicRestriction

Register

MT029270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel